Phase 3 Parkinson's Disease Trial, Recruiting NCT05576818 Sponsor: Tanta University Condition: Parkinson's Disease
Back to Parkinsons Disease

Phase 3 Parkinson's Disease Trial, Recruiting

NCT05576818
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 45 and 65 years old
  • You are male or female
  • You have been diagnosed with Parkinson's disease and are currently taking medication to replace or boost dopamine
  • Your Parkinson's disease is at a moderate level of severity — not at the most advanced stage (confirm with trial site)

Who may not be able to join:

  • You have taken antibiotics in the past month or are currently taking them
  • You have used any probiotic products (such as probiotic supplements or drinks) in the past two weeks or are currently using them
  • You are scheduled to have surgery on your digestive system, or you have already had such surgery
  • You have a known allergy to probiotics
  • You are receiving nutrition through a feeding tube or directly into your veins
  • You have been diagnosed with depression and/or psychosis
  • You are taking antioxidant or anti-inflammatory medications
  • You have an overactive thyroid gland (hyperthyroidism)
  • You have an inflammatory condition or a condition that involves high levels of oxidative stress in the body (confirm with trial site)
  • You are a smoker
  • Your Parkinson's disease is at the most severe stage (stage 5 on the Hoehn & Yahr scale — meaning full dependence on others for movement)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 201205280849

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Tanta University
Registry
ClinicalTrials.gov
Start date
30 June 2022
Est. completion
1 June 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

The change in MDS-Unified Parkinson's Disease Rating Scale.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov